Chronic Lymphocytic Leukemia | Specialty

Ibrutinib Plus Rituximab Approved in Europe for Frontline CLL

September 10th 2020

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Dr. Woyach on the Role of Acalabrutinib in CLL

September 10th 2020

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Dr. Ghosh on Unanswered Questions With BTK Inhibitors in CLL/SLL

September 10th 2020

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ofatumumab to Be Available Through a Patient Access Program for CLL

September 10th 2020

Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.

Dr. Woyach on Remaining Sequencing Questions in CLL

September 9th 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Dr. Flinn on the Design of a Phase 2 Trial of Zanubrutinib in CLL/SLL

August 31st 2020

Ian W. Flinn, MD, PhD, discusses the design of a phase 2 trial evaluating zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Building on Current Understandings of BTK Inhibition in CLL, MCL

August 19th 2020

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

August 14th 2020

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Dr. Ghosh on the Role of MRD in CLL

August 12th 2020

Nilanjan Ghosh, MD, PhD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Dr. Ghia on Lack of OS Advantage With Acalabrutinib Per ASCEND Trial in CLL

August 10th 2020

Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.

FDA Clears First MRD Assay for Chronic Lymphocytic Leukemia

August 6th 2020

The FDA has cleared the clonoSEQ® assay to identify and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.

Dr. Al-Sawaf on New Safety Signals With Venetoclax/Obinutuzumab in the CLL14 Trial

August 4th 2020

Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.

Future Directions in CLL

July 30th 2020

Novel Therapies for CLL

July 30th 2020

PI3 Kinase Inhibitors in CLL

July 30th 2020

Therapeutic Sequencing in CLL

July 30th 2020

BTK Inhibitors in Relapsed/Refractory CLL

July 30th 2020

MURANO Trial Update in R/R CLL

July 30th 2020

Utility of MRD Testing in CLL Management

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

July 30th 2020